//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGFR-mutated metastatic NSCLC. #lungcancer www.onclive.com/view/dr-gira...
2mo
Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.
Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC | OncLive
www.onclive.com
Addario Lung Cancer Medical Institute (ALCMI)